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Abstract
Background: CD147 is a widely distributed cell surface glycoprotein that belongs to the Ig superfamily. CD147 has 
been implicated in numerous physiological and pathological activities. Enriched on the surface of many tumor cells, 
CD147 promotes tumor growth, invasion, metastasis and angiogenesis and confers resistance to some 
chemotherapeutic drugs. In this study, we investigated the possible role of CD147 in the progression of gastric cancer.
Methods: Short hairpin RNA (shRNA) expressing vectors targeting CD147 were constructed and transfected into 
human gastric cancer cells SGC7901 and CD147 expression was monitored by quantitative realtime RT-PCR and 
Western blot. Cell proliferation, the activities of MMP-2 and MMP-9, the invasive potential and chemosensitivity to 
cisplatin of SGC7901 cells were determined by MTT, gelatin zymography, Transwell invasion assay and MTT, 
respectively.
Results: Down-regulation of CD147 by RNAi approach led to decreased cell proliferation, MMP-2 and MMP-9 activities 
and invasive potential of SGC7901 cells as well as increased chemosensitivity to cisplatin.
Conclusion: CD147 involves in proliferation, invasion and chemosensitivity of human gastric cancer cell line SGC7901, 
indicating that CD147 may be a promising therapeutic target for gastric cancer.
Background
Although the incidence and mortality of gastric cancer
have fallen dramatically over the past 50 years [1], it
remains the fourth most common cancer and the second
leading cause of cancer-related death worldwide [2,3].
Gastric cancer traditionally carries a very poor prognosis
because of late presentation at an advanced stage of dis-
ease and remains a great clinical challenge. Therefore, a
better understanding of the molecular mechanisms
underlying gastric cancer formation and progression
should be helpful in developing more effective treatments
for this disease.
The metastatic process is dependent on the degrada-
tion of the extracellular matrix (ECM) both at primary
tumor site and at secondary colonization site. Matrix
metalloproteinases (MMPs), a family of zinc-dependent
proteolytic enzymes, play a central role in the degradative
process. High levels of MMPs have been frequently found
at the tumor-stroma interface, most of which are
expressed by stromal cells rather than by tumor cells
themselves [4]. A search for MMP inducing factors in
tumor cells led to the identification of CD147/EMMPRIN
[5]. CD147 is a highly glycosylated cell surface transmem-
brane protein which is expressed at high levels in variety
of malignant human cancers. In cells, CD147 is expressed
in various forms, including high glycosylated (HG 45-65
kDa) and low glycosylated (LG 32-44 kDa) forms as well
as the native 27-kDa protein. CD147 has been demon-
strated to stimulate production of MMP-1, -2, -3, -9, -14,
and -15 in peritumoral fibroblasts and endothelial cells
therefore facilitate tumor invasion and metastasis [6].
Recently, CD147 was found to stimulate tumor angiogen-
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esis by elevating vascular endothelial growth factor
(VEGF) and MMP expression in neighboring fibroblasts
via the PI3K-AKT signaling pathway [7,8]. CD147 is also
i n v o l v e d  i n  m u l t i d r u g  r e s i s t a n c e  o f  c a n c e r  c e l l s  v i a
hyaluronan-mediated activating of ErbB2 signaling and
cell survival pathway activities [9-11].
Zheng et al. [12] investigated the role of CD147 in pro-
gression and angiogenesis of gastric cancer. CD147
expression was gradually increased from normal mucosa
to carcinomas through hyperplastic or metaplastic
mucosa of the stomach, and its expression was positively
correlated with tumor size, depth of invasion, lymphatic
invasion and expression of ki-67, MMP-2, MMP-9 and
VEGF in gastric cancer. However, the effect of reducing
CD147 levels by genetic methods in established gastric
cancer cells has not been investigated, the study of which
would help understand its role in the malignant pheno-
type. Therefore, in this study, we silenced CD147 expres-
sion in human gastric cancer cell line SGC7901 by RNA
interference (RNAi) to determine its effect on the prolif-
eration and invasion ability as well as the chemosensitiv-
ity of SGC7901 cells.
Methods
Cell culture
Human gastric cancer cell line SGC7901 was provided by
Digestive Department of Jiangsu Province Hospital,
China. Cells were cultured with DMEM medium (Gibco
BRL, Grand Island, NY, USA) supplemented with 10%
newborn calf serum (Gibco BRL, Grand Island, NY, USA)
at 37°C in a humidified atmosphere containing 5% CO2.
Construction of shRNA expression vectors
The vector pSilencer 3.1-H1 neo (Ambion Inc., Austin,
TX, USA) was used to generate short hairpin RNA
(shRNA) specific for CD147. Two different regions of
CD147 mRNA [GenBank: AB085790] were selected as
the RNAi target sites: 370-390 bp and 808-828 bp [13].
Two pairs of template oligonucleotides, each encoding
one of the target sequences were designed and synthe-
sized (designated as shRNA1 and shRNA2 respectively),
and another pair of oligonucleotides (designated as
shRNA-control) encoding a non-specific shRNA used as
a negative control was also synthesized (Table 1). These
oligonucleotides were annealed and subcloned into the
Hind III and BamH I sites of the vector according to the
manufacturer's instructions. These recombinant vectors
were designated as pSilencer-shRNA1, pSilencer-
shRNA2 and pSilencer-shRNA-control, respectively.
They were sequenced for correct ligation.
Transfection of cells
SGC7901 cells were plated in six-well plates at a density
of 3 × 105 cells per well and incubated overnight. Cells
were transfected with pSilencer-shRNA1, pSilencer-
shRNA2 and pSilencer-shRNA-control respectively using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions. Forty-eight
hours after transfection, SGC7901 cells were diluted to
1:10 for passage and neomycin resistance clones were
selected in the medium containing 400 μg/ml G418
(Gibco BRL, Grand Island, NY, USA) for two weeks. The
positive clones were picked and expanded to establish cell
lines. The stable transfection cell clones, designated as
SGC7901/shRNA1, SGC7901/shRNA2 and SGC7901/
shRNA-control, were verified by quantitative realtime
RT-PCR and Western blot analysis.
Quantitative Realtime RT-PCR Assays
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). RNA integrity was con-
firmed by electrophoresis on ethidium bromide-stained
1% agarose gel. The primer sequences used were for
CD147:(sense)5'-CCATGCTGGTCTGCAAGTCAG-3'
and(antisense) 5'-CCGTTCATGAGGGCCTTGTC-3'; β-
actin(sense)5'-CTGGAACGGTGAAGGTGACA-3' and
(antisense) 5'-AAGGGACTTCCTGTAACAACGCA-3'.
The mRNA level for CD147 was analyzed by one-step
realtime reverse transcriptase polymerase chain reaction
with RNA-direct™ SYBR Green Realtime PCR Master
Mix (Toyobo Co., Ltd., Osaka, Japan) according to the
manufacturer's instructions. Cycling conditions were:
90°C for 30 s, 61°C for 20 min, 95°C for 60 s, then 40
cycles at 95°C for 15 s, 60°C for 1 min. The mRNA level
for CD147 of each sample was normalized to that of the
β-actin mRNA and presented as unit values of 2^ [Ct(β-
actin) - Ct(CD147)]. The amplification was monitored on an
ABI prism 7500 realtime PCR apparatus (Applied Biosys-
tems, USA).
Western blot analysis
Cells were harvested from flasks, and lysed with ice-cold
lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1
mM MgCl2, 100 μg/ml PMSF and 1% Triton X-100) for 30
min on ice. Cell lysates were then collected after centrifu-
gation at 12,000 rpm for 5 min at 4°C. Equal amounts (50
μg) of lysate proteins were separated on 10% SDS-PAGE
gels, and transblotted onto PVDF membranes (Pall Cor-
poration, USA). After blocking with 5% non-fat dry milk
in TBST buffer (10 mM Tris, pH 7.5, 150 mM NaCl, and
0.05% Tween 20) for 2 h at room temperature, the mem-
branes were probed with 1:500 dilution of anti-CD147
(Santa Cruz, CA, USA) or anti-β-actin (Santa Cruz, CA,
USA) antibodies at room temperature for 2 h, followed by
incubation in a 1:2000 dilution of secondary antibodies
conjugated to horseradish peroxidase (Santa Cruz, CA,
USA) for 1 h at room temperature. Protein bands were
detected using ECL detection system (Boster, Wuhan,Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:61
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China). All of the Western blots were performed at least
three times.
Cell Proliferation Assay
Before the cell proliferation assay, trypan blue exclusion
test of cell viability was performed and the viability of the
three groups of cells (SGC7901, SGC7901/shRNA-con-
trol and SGC7901/shRNA2) was >98%. Cell proliferation
in vitro was analyzed with 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT, Sigma, St. Louis,
MO, USA). Briefly, 2000 cells of each group were plated
per well in three 96-well microplates in 200 μL of
medium. After 24, 48, and 72 h of culture respectively, 20
μL of MTT substrate (5 mg/mL in PBS) was added to
each well, and the plates were returned to standard tissue
incubator conditions for an additional 6 h. The medium
was then removed, the cells were solubilized in 150 μl of
dimethyl sulfoxide, and colorimetric analysis was per-
formed (wavelength, 490 nm). The inhibition rate was
calculated as [1 - (OD value of the transfectant/OD value
of untreated SGC7901)] × 100%. Each experiment was
done in triplicate.
Gelatin zymography
Protein concentrations in conditioned medium were
determined using the bicinchonic acid method (BCA kit)
(Pierce, Rockford, IL, USA). The gelatinolytic activities of
MMP-2 and MMP-9 in the conditioned medium were
assayed by electrophoresis on 10% polyacrylamide gels
containing 1 mg/ml of gelatin (type A, Sigma, St. Louis,
MO, USA) at 4°C. PAGE gels were run at 120 V, washed
in 2.5% Triton X-100 for 1 h, and then incubated for 20 h
at 37°C in activation buffer (50 mM Tris-HCl, pH 7.5, 5
mM CaCl2, 0.02% Brij-35). After staining with Coomassie
Blue (10% glacial acetic acid, 30% methanol and 0.5%
Coomassie Blue) for 3 h, the gel was destained with a
solution of 10% glacial acetic acid, and 50% methanol
without Coomassie Blue for 1 h. White lysis zones indi-
cating gelatin degradation were revealed by staining with
Coomassie blue R-250.
Invasion assay
Appropriate Matrigel (BD Biosciences, Bedford, MA,
USA)was added to the upper chamber of the transwell
apparatus with 8-μm pore size membrane (Costar, Cam-
bridge, MA, USA). After the Matrigel solidified at 37°C,
serum-free DMEM containing 1 × 105 cells in 100 μl was
added into the upper chamber; the lower chamber
received 500 μl of 10% FBS-containing medium. After
incubated at 37°C for 24 h, membranes coated with
Matrigel were swabbed with a cotton swab and fixed with
100% methanol for 10 min. The membranes with cells
were soaked in 0.1% crystal violet for 10 min and then
washed with distilled water. The number of cells attached
to the lower surface of the polycarbonate filter was
counted at 400× magnification under a light microscope.
Results were expressed as mean of triplicate experiments.
Drug sensitivity assay
To assess the chemosensitivity to anti-tumor drug cispla-
tin, the cells were seeded in triplicate on 96-well plates at
1 × 104 cells/well and incubated for 24 h. The medium
was then removed and replaced with fresh medium con-
taining cisplatin (Sigma, St. Louis, MO, USA) with vary-
ing concentrations: 0.1 × peak plasma concentration
(PPC), 1 × PPC and 10 × PPC. After 48 h, cells were
treated with MTT as described earlier. The inhibition
rate was calculated as [1 - OD490(cisplatin+)/OD490(cisplatin-)] ×
100%. The assay was repeated three times.
Statistical analysis
SPSS13.0 software was used. Each assay was performed at
least three times. The data were expressed as mean ± SD,
and Student's t test was used to determine the signifi-
cance of differences in multiple comparisons. p < 0.05
was considered to be statistically significant.
Results
shRNA targeting CD147 suppresses CD147 expression in 
SGC7901 cells
The silencing effects of different CD147 specific shRNAs
in SGC7901 cells were first evaluated using realtime RT-
Table 1: The sequences of the designed CD147 specific shRNAs
shRNA Sequence
shRNA1 5'-GATCCGTCGTCAGAACACATCAACTTCAAGAGAGTTGATGTGTTCTGACGACTTTTTTGGAAA-3'
5'-AGCTTTTCCAAAAAAGTCGTCAGAACACATCAACTCTCTTGAAGTTGATGTGTTCTGACGACG-3'
shRNA2 5'-GATCCGTGACAAAGGCAAGAACGTCTTCAAGAGAGACGTTCTTGCCTTTGTCATTTTTTGGAAA-3'
5'-AGCTTTTCCAAAAAATGACAAAGGCAAGAACGTCTCTCTTGAAGACGTTCTTGCCTTTGTCACG-3'
shRNA-control 5'-GATCCACTACCGTTGTTATAGGTGTTCAAGAGACACCTATAACAACGGTAGTTTTTTTGGAAA-3'
5'-AGCTTTTCCAAAAAAACTACCGTTGTTATAGGTGTCTCTTGAACACCTATAACAACGGTAGTG-3'Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:61
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PCR. A 27.6% and an 82.7% CD147 mRNA inhibition for
shRNA1 and shRNA2 was achieved respectively com-
pared to untreated SGC7901 cells (Fig. 1A), while
shRNA-control showed no effects. Western blot analysis
confirmed the down-regulation of CD147 protein by
transfection of shRNA expressing vector (Fig. 1B). Thus,
SGC7901/shRNA2 cell clone was chosen for further
experiments.
CD147 silencing reduces the proliferation of SGC7901 cells
Next, we determined the proliferation of SGC7901,
SGC7901/shRNA-control and SGC7901/shRNA2
respectively. As shown in Fig. 2, compared with
SGC7901, the proliferation of SGC7901/shRNA2 was
inhibited to 74.85% (p < 0.01), 77.86% (p < 0.01) and
74.79% (p < 0.01) at 24, 48 and 72 h, respectively. There
was no significant difference between SGC7901/shRNA-
control and SGC7901 (p > 0.05).
CD147 silencing reduces MMP-2 and MMP-9 activities in 
SGC7901 cells
Since MMP-2 and MMP-9 play critical role in tumor cell
invasion, we examined the effects of CD147 silencing on
the enzyme activities of MMP-2 and MMP-9 using gela-
tin zymography. The gelatinolytic activities of both
MMP-2 and MMP-9 were found to be reduced markedly
in SGC7901/shRNA2 compared with SGC7901 and
SGC7901/shRNA-control (p < 0.01) (Fig. 3). There was
no significant difference between SGC7901/shRNA-con-
trol and SGC7901 (p > 0.05).
CD147 silencing reduces the invasive ability of SGC7901 
cells in vitro
To examine whether the down-regulation of CD147 in
SGC7901 affected its invasive ability, we performed an in
vitro Matrigel Transwell analysis. The results showed that
SGC7901 and SGC7901/shRNA-control cells had a simi-
lar ability to pass through the Matrigel coated filter,
because the numbers of invading cells were roughly equal
(Fig 4). The number of SGC7901/shRNA2 cells (25.60 ±
3.28, p < 0.01) passing through the Matrigel was markedly
Figure 1 CD147 specific shRNAs results in the reduction of CD147 mRNA and protein levels in SGC7901 cells. (A). Relative mRNA levels were 
analysed by quantitative RT-PCR. β-actin was used as normalization control. *p < 0.01 compared with SGC7901. (B). Western blot analysis of CD147 
protein expressions. β-actin was used as loading control. HG:high glycosylated form; LG: low glycosylated form.
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lower than the numbers of SGC7901 (55.80 ± 5.03) and
SGC7901/shRNA-control (54.40 ± 4.35) cells. There was
no significant difference between SGC7901/shRNA-con-
trol and SGC7901 (p > 0.05).
Silencing of CD147 in SGC7901 cells results in increased 
chemosensitivity to cisplatin
CD147 was found to be overexpressed in multidrug resis-
tance tumor cells and could confer resistance to some
anti-tumor drugs. We next investigated whether inhibi-
tion of CD147 by RNAi affected the sensitivity of
SGC7901 cells to the anti-tumor drug cisplatin. As shown
in Fig. 5, the inhibition rate in SGC7901/shRNA2 was
markedly enhanced at all concentrations examined com-
pared with SGC7901 and SGC7901/shRNA-control (p <
0.01). There was no significant difference between
SGC7901/shRNA-control and SGC7901 (p > 0.05).
Discussion
CD147, also designated EMMPRIN (extracellular matrix
metalloproteinase inducer), is a cell surface glycoprotein
which belongs to the immunoglobulin superfamily. As
CD147 is highly expressed in most tumors and was
shown to increase tumor invasion, most studies so far
focuses on its role in cancer progression. However, its
expression is not limited to tumor cells and was shown to
be expressed in many cell types, including haematopoi-
etic, epithelial, endothelial cells and leukocytes [14].
Gene silencing by RNA interference has emerged as a
powerful method that is useful for the study of functional
genomics [15]. Here, we successfully transfected two shR-
NAs targeting CD147 gene into human gastric cancer cell
line SGC7901. Two stable cell clones SGC7901/shRNA1
and SGC7901/shRNA2 were obtained. CD147 expression
was effectively inhibited at both mRNA and protein levels
by shRNA2, while the shRNA1 was less efficient. These
results indicated that shRNA targeting different sites of
the same mRNA might be different in silencing efficiency.
We then examined the effect of CD147 silencing on the
proliferation of SGC7901 cells. The proliferation poten-
tial of SGC7901/shRNA2 cells was suppressed compared
with that of the control SGC7901 cells. Chen et al. and Jia
et al. also found that down-regulation of CD147 inhibited
the proliferation of human malignant melanoma cell line
A375 and murine lymphoid neoplasm cell line P388D1,
respectively [13,16]. It was found that CD147 and cyclo-
philin A (CypA) were both highly expressed in pancreatic
cancer, and exogenous CypA promoted pancreatic cancer
cell growth, which may be mediated through the interac-
tion with its cellular receptor CD147 and the activation of
ERK1/2 and p38 MAPKs [17].
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases, play a crucial role in ECM
degradation associated with cancer cell invasion, metas-
tasis and angiogenesis [18]. Among members of the
MMP family, MMP-2 (gelatinase-A) and MMP-9 (gelati-
nase-B) are particularly up-regulated in malignant
tumors and contribute to the invasion and metastatic
spread of cancer cells by degrading type IV collagen, a
major component of the basement membrane [19]. The
degree of MMP expression by stromal fibroblasts has
been shown to be correlated with CD147 expression lev-
els in a wide range of tumors [20]. CD147 was reported as
the most constantly upregulated protein in metastatic
Figure 3 Gelatin zymography analysis of MMP-2 and MMP-9 activity in SGC7901 cells. Cells were incubated for 24 h and conditioned media 
were used for the measurement of MMP-2 and MMP-9 protein levels by gelatin zymography. (A) Photographs of the MMP-2 and MMP-9 bands, which 
are representative of three independent experiments, are shown. (B) Quantitative analysis of the bands. *p < 0.01 compared with SGC7901 and 
SGC7901/shRNA-control.
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cells, suggesting a central role in tumor progression and
early metastasis [21]. Transfection of CD147 cDNA into
human MDA-MB436 breast cancer cells resulted in an
enhancement of tumor growth and an increase in meta-
static incidences, both of which were directly correlated
with high levels of tumor-derived MMP-2 and MMP-9
[22]. Among the MMPs induced by CD147, malignant
progression has been most closely correlated with the
expression of MMP-2 in several forms of cancer, and the
increased levels of MMP-2 are typically indicative of poor
prognostic outcome [23]. In our study, it was showed that
downregulation of CD147 expression in human gastric
cancer cells reduced the secretion of MMP-2 and MMP-
9, thus inhibited the invasion ability of gastric cancer cells
through the reconstituted basement membrane in vitro.
Multidrug resistance (MDR) is an important cause of
treatment failure and mortality in gastric cancer patients.
Overexpression of CD147 was observed in many MDR
cancer cells [10]. CD147 plays a role in tumor MDR via
different ways. CD147 was found to increase the expres-
sion of ATP-binding cassette (ABC) transporter families,
such as P-glycoprotein (MDR1/ABCB1) [24,25]. CD147
was also shown to stimulate phosphoinositide 3-kinase/
AKT cell survival signaling pathway, which is an anti-
apoptotic pathway upregulated in most malignant cancer
cells. The increase in anti-apoptotic signaling in turn
leads to increased multidrug resistance. This effect of
CD147 depends on stimulation of the production of
hyaluronan, a pericellular polysaccharide [9,11]. The
inhibition of CD147 expression via RNAi could increase
the chemosensitivity to anti-tumor drugs in human ovar-
Figure 4 Effects of CD147 specific shRNA on invasion of SGC7901 cells. (A)Crystal violet staining results of the lower surface filters showed that 
the cells passed through the filter and attached to the lower side of the filter (400×). (B) The average number of cells that invaded through the filter 
was counted. The data were obstained from three independent experiments. *p < 0.01 compared with SGC7901 and SGC7901/shRNA-control.
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ian cancer cell line and human oral squamous cell carci-
noma cell line [26,27]. In the present study, silencing
CD147 expression increased the chemosensitivity to cis-
platin in human gastric cancer cell line SGC7901, sug-
gesting CD147 is an adjuvant chemotherapy target for
gastric cancer.
Conclusions
This report showed that the silencing of CD147 by RNAi
inhibited the proliferation and invasion of human gastric
cancer cell line SGC7901 in vitro and increased its
chemosensitivity to the anti-tumor drug cisplatin. Our
findings suggested that CD147 might be a promising tar-
get for gastric cancer treatment.
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Figure 5 Effects of CD147 specific shRNA on cisplatin sensitivity 
of SGC7901 cells. SGC7901, SGC7901/shRNA-control and SGC7901/
shRNA2 were treated with various concentrations of cisplatin. Cell vi-
alility was determined by MTT assay. *p < 0.01 compared with 
SGC7901 and SGC7901/shRNA-control.
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